Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - atezolüsumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastilised ained - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Euroopa Liit - eesti - EMA (European Medicines Agency)

recordati ireland ltd - silodosiin - eesnäärme hüperplaasia - urologicals, alfa-adrenoreceptor antagonistid - ravi nähud ja sümptomid eesnäärme healoomulise hüperplaasia (bph), täiskasvanud mehed.

Eesti - eesti - Ravimiamet

ever neuro pharma gmbh - urapidiil - infusioonilahuse kontsentraat - 5mg 1ml 20ml 5tk

Eesti - eesti - Ravimiamet

recordati ireland limited - enalapriil+lerkanidipiin - õhukese polümeerikattega tablett - 20mg+10mg 14tk; 20mg+10mg 30tk; 20mg+10mg 50tk; 20mg+10mg 56tk; 20mg+10mg 98tk; 20mg+10mg 7tk; 20mg+10mg 90tk; 20mg+10mg 35tk; 20mg+10mg 100tk

Eesti - eesti - Ravimiamet

dr. august wolff gmbh & co. kg arzneimittel - metronidasool - õhukese polümeerikattega tablett + vaginaalsuposiit - 250mg/100mg 12tk / 6tk

Eesti - eesti - Ravimiamet

recordati ireland limited - enalapriil+lerkanidipiin - õhukese polümeerikattega tablett - 10mg+10mg 56tk; 10mg+10mg 90tk; 10mg+10mg 42tk; 10mg+10mg 50tk; 10mg+10mg 7tk; 10mg+10mg 30tk; 10mg+10mg 100tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - zofenopriil+hüdroklorotiasiid - õhukese polümeerikattega tablett - 30mg+12,5mg 30tk; 30mg+12,5mg 50tk; 30mg+12,5mg 28tk; 30mg+12,5mg 100tk; 30mg+12,5mg 90tk; 30mg+12,5mg 56tk

Eesti - eesti - Ravimiamet

recordati ireland limited - enalapriil+lerkanidipiin - õhukese polümeerikattega tablett - 10mg+10mg 50tk; 10mg+10mg 30tk; 10mg+10mg 100tk; 10mg+10mg 28tk; 10mg+10mg 90tk; 10mg+10mg 42tk

Eesti - eesti - Ravimiamet

sanofi pasteur - gripiviirus, inaktiveeritud, tükeldatud viirus või pinnaantigeen - süstesuspensioon süstlis - 1annus 0.5ml 0.5ml 50tk; 1annus 0.5ml 0.5ml 10tk; 1annus 0.5ml 0.5ml 1tk; 1annus 0.5ml 0.5ml 20tk

Eesti - eesti - Ravimiamet

glaxosmithkline biologicals - difteeria toksoid+läkaköha tekitaja, puhastatud antigeen+teetanuse toksoid+poliomüeliidi koguviirus, trivalentne, inaktiveeritud - süstesuspensioon süstlis - 1annus+1annus+1annus+1annus 0.5ml 0.5ml 10tk; 1annus+1annus+1annus+1annus 0.5ml 0.5ml 1tk